Receptos Was A Biopharmaceutical Company Founded In 2009Focusing On Immunology And Metabolic Disordersin August 2015It Became A Wholly Owned Subsidiary Of Celgene Corporation Following A $7 2 Billion Acquisitionthis Integration Aimed To Enhance Celgene S Pipeline In Therapies For Immune Inflammatory Diseases Receptos Specialized In Developing Small Molecule Therapeutics That Target G Protein Coupled Receptorsgpcrs Its Lead Candidateozanimodis A Modulator Investigated For Autoimmune Conditions Such As Multiple Sclerosis And Ulcerative Colitisthe Company Utilized Technologies Like Mixpanel For Analytics And Amazon Web Services For Cloud Infrastructureemphasizing Gpcr Targeted Drug Discoveryafter The Acquisitionreceptos Ceased Independent Operations And Its Assets Were Incorporated Into Celgene S Broader Portfolio
No conferences found for this company.
| Company Name | Receptos Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
